EGFR and non-small cell lung carcinoma: Challa et al56 testified that both wild‐type and mutant EGFR directly interacts with IKBKE, whereas only mutant EGFR, which tended to develop resistance to therapeutic EGFR inhibitors, phosphorylated IKBKE on Tyr153 and Tyr179 residues to promote proliferation and invasion of NSCLC in vitro and in vivo.